Compare HMN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HMN | FTRE |
|---|---|---|
| Founded | 1945 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 829.3M |
| IPO Year | 1996 | 2023 |
| Metric | HMN | FTRE |
|---|---|---|
| Price | $45.55 | $10.42 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $47.33 | $14.06 |
| AVG Volume (30 Days) | 179.2K | ★ 891.8K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | ★ 57.26 | N/A |
| EPS | ★ 3.90 | N/A |
| Revenue | $1,701,400,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $7.56 | N/A |
| Revenue Next Year | $4.64 | $3.09 |
| P/E Ratio | $11.46 | ★ N/A |
| Revenue Growth | ★ 6.66 | 1.00 |
| 52 Week Low | $38.76 | $3.97 |
| 52 Week High | $48.33 | $18.67 |
| Indicator | HMN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 65.78 | 57.60 |
| Support Level | $45.44 | $8.80 |
| Resistance Level | $45.67 | $10.47 |
| Average True Range (ATR) | 0.95 | 0.66 |
| MACD | 0.20 | 0.21 |
| Stochastic Oscillator | 90.24 | 91.91 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.